Research ArticleBasic Science Investigations
Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles
Eric D. Hostetler, Abbas M. Walji, Zhizhen Zeng, Patricia Miller, Idriss Bennacef, Cristian Salinas, Brett Connolly, Liza Gantert, Hyking Haley, Marie Holahan, Mona Purcell, Kerry Riffel, Talakad G. Lohith, Paul Coleman, Aileen Soriano, Aimie Ogawa, Serena Xu, Xiaoping Zhang, Elizabeth Joshi, Joseph Della Rocca, David Hesk, David J. Schenk and Jeffrey L. Evelhoch
Journal of Nuclear Medicine October 2016, 57 (10) 1599-1606; DOI: https://doi.org/10.2967/jnumed.115.171678
Eric D. Hostetler
1Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
Abbas M. Walji
2Discovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania
Zhizhen Zeng
1Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
Patricia Miller
1Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
Idriss Bennacef
1Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
Cristian Salinas
1Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
Brett Connolly
1Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
Liza Gantert
1Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
Hyking Haley
1Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
Marie Holahan
1Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
Mona Purcell
1Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
Kerry Riffel
1Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
Talakad G. Lohith
1Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
Paul Coleman
2Discovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania
Aileen Soriano
3Pharmacology, Merck & Co., Inc., Kenilworth, New Jersey
Aimie Ogawa
3Pharmacology, Merck & Co., Inc., Kenilworth, New Jersey
Serena Xu
3Pharmacology, Merck & Co., Inc., Kenilworth, New Jersey
Xiaoping Zhang
3Pharmacology, Merck & Co., Inc., Kenilworth, New Jersey
Elizabeth Joshi
4Drug Metabolism, Merck & Co., Inc., West Point, Pennsylvania
Joseph Della Rocca
5Discovery Pharmaceutical Sciences, Merck & Co., Inc., West Point, Pennsylvania; and
David Hesk
6Labelled Compound Synthesis, Merck & Co., Inc., Rahway, New Jersey
David J. Schenk
6Labelled Compound Synthesis, Merck & Co., Inc., Rahway, New Jersey
Jeffrey L. Evelhoch
1Translational Biomarkers, Merck & Co., Inc., West Point, Pennsylvania
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 57, Issue 10
October 1, 2016
Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles
Eric D. Hostetler, Abbas M. Walji, Zhizhen Zeng, Patricia Miller, Idriss Bennacef, Cristian Salinas, Brett Connolly, Liza Gantert, Hyking Haley, Marie Holahan, Mona Purcell, Kerry Riffel, Talakad G. Lohith, Paul Coleman, Aileen Soriano, Aimie Ogawa, Serena Xu, Xiaoping Zhang, Elizabeth Joshi, Joseph Della Rocca, David Hesk, David J. Schenk, Jeffrey L. Evelhoch
Journal of Nuclear Medicine Oct 2016, 57 (10) 1599-1606; DOI: 10.2967/jnumed.115.171678
Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles
Eric D. Hostetler, Abbas M. Walji, Zhizhen Zeng, Patricia Miller, Idriss Bennacef, Cristian Salinas, Brett Connolly, Liza Gantert, Hyking Haley, Marie Holahan, Mona Purcell, Kerry Riffel, Talakad G. Lohith, Paul Coleman, Aileen Soriano, Aimie Ogawa, Serena Xu, Xiaoping Zhang, Elizabeth Joshi, Joseph Della Rocca, David Hesk, David J. Schenk, Jeffrey L. Evelhoch
Journal of Nuclear Medicine Oct 2016, 57 (10) 1599-1606; DOI: 10.2967/jnumed.115.171678
Jump to section
Related Articles
Cited By...
- Biostatistical Estimation of Tau Threshold Hallmarks (BETTH) Algorithm for Human Tau PET Imaging Studies
- Cryo-EM structure of Alzheimers disease tau filaments with PET ligand MK-6240
- The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework
- The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework
- Measurement of Cerebral Perfusion Indices from the Early Phase of [18F]MK6240 Dynamic Tau PET Imaging
- The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [18F]MK6240 Tau PET in Target Regions
- A Visual Interpretation Algorithm for Assessing Brain Tauopathy with 18F-MK-6240 PET
- In Vivo Detection of Neurofibrillary Tangles by 18F-MK-6240 PET/MR in Patients With Ischemic Stroke
- High-Contrast PET imaging with [18F]-NT160, a Class-IIa Histone Deacetylase (Class-IIa HDAC) Probe for In Vivo Imaging of Epigenetic Machinery in the Central Nervous System
- The association of age-related and off-target retention with longitudinal quantification of [18F]MK6240 tau-PET in target regions
- Rates of regional tau accumulation in ageing and across the Alzheimers disease continuum: An AIBL 18F-MK6240 PET study
- Direct Comparison of the Tau PET Tracers 18F-Flortaucipir and 18F-MK-6240 in Human Subjects
- Independent information from PET, CSF and plasma biomarkers of tau pathology in Alzheimers disease
- Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE {varepsilon}4, and Cognitive Impairment
- Olfactory impairment is related to tau pathology and neuroinflammation in Alzheimers disease
- High-contrast in-vivo imaging of tau pathologies in Alzheimers and non-Alzheimers disease tauopathies
- Amyloid duration is associated with preclinical cognitive decline and tau PET
- In vivo characterization and quantification of neurofibrillary tau PET radioligand [18F]MK-6240 in humans from Alzheimers disease dementia to young controls
- First in-human PET study of 3 novel tau radiopharmaceuticals: [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948
- Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with 18F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles
- In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls
- Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects
- Preclinical Evaluation of 18F-RO6958948, 11C-RO6931643, and 11C-RO6924963 as Novel PET Radiotracers for Imaging Tau Aggregates in Alzheimer Disease
- Is Tau Imaging More Than Just Upside-Down 18F-FDG Imaging?
- In Vivo Comparison of Tau Radioligands 18F-THK-5351 and 18F-THK-5317